Miquel Tarón

19.4k total citations · 1 hit paper
168 papers, 7.1k citations indexed

About

Miquel Tarón is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Miquel Tarón has authored 168 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Pulmonary and Respiratory Medicine, 85 papers in Molecular Biology and 77 papers in Oncology. Recurrent topics in Miquel Tarón's work include Lung Cancer Treatments and Mutations (95 papers), Cancer Genomics and Diagnostics (49 papers) and DNA Repair Mechanisms (28 papers). Miquel Tarón is often cited by papers focused on Lung Cancer Treatments and Mutations (95 papers), Cancer Genomics and Diagnostics (49 papers) and DNA Repair Mechanisms (28 papers). Miquel Tarón collaborates with scholars based in Spain, United States and Italy. Miquel Tarón's co-authors include Rafael Rosell, Rafael Rosell, José Javier Sánchez, Carlos Camps, Pedro Méndez, Noemı́ Reguart, José Miguel Sánchez, Dolores Isla, Enriqueta Felip and Kathleen D. Danenberg and has published in prestigious journals such as Nature, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Miquel Tarón

161 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 551 citations David R. Gandara, Vicente Alberola et al. PubMed profile →

Peers

Miquel Tarón

PRM

ONCOL

SURGE

José Javier Sánchez Spain

Rafael Rosell Spain

Philip C. Mack United States

Hisayuki Shigematsu Japan

Dhananjay Chitale United States

Petri Bono Finland

Fred R. Hirsch United States

Martin Filipits Austria

Jennifer J. Wheler United States

Lucian R. Chirieac United States

José Javier Sánchez Spain

Miquel Tarón

3.0k ×0.8

2.8k ×0.8

PRM

3.0k ×0.9

ONCOL

1.6k ×0.8

539 ×0.7

SURGE

Citations per year, relative to Miquel Tarón Miquel Tarón (= 1×) peers José Javier Sánchez

Countries citing papers authored by Miquel Tarón

Since Specialization

Citations

This map shows the geographic impact of Miquel Tarón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miquel Tarón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miquel Tarón more than expected).

Fields of papers citing papers by Miquel Tarón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miquel Tarón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miquel Tarón. The network helps show where Miquel Tarón may publish in the future.

Co-authorship network of co-authors of Miquel Tarón

This figure shows the co-authorship network connecting the top 25 collaborators of Miquel Tarón. A scholar is included among the top collaborators of Miquel Tarón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miquel Tarón. Miquel Tarón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rodríguez‐Vicente, Ana E., Eva Lumbreras, Jesús María Hernández-Sánchez, et al.. (2016). Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metabolism and Personalized Therapy. 31(1). 25–34. 20 indexed citations

Rosell, Antoni, Núria Rodríguez, Eduard Monsó, et al.. (2016). Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients. Lung Cancer. 94. 102–107. 1 indexed citations

Costa, Carlota, Miguel Angel Molina, Ana Drozdowskyj, et al.. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. 20(7). 2001–2010. 180 indexed citations

Reguart, Noemı́, Rafael Rosell, Felipe Cardenal, et al.. (2014). Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 84(2). 161–167. 72 indexed citations

Skrzypski, Marcin, Rafał Dziadziuszko, Ewa Jassem, et al.. (2013). Main Histologic Types of Non–Small-Cell Lung Cancer Differ in Expression of Prognosis-related Genes. Clinical Lung Cancer. 14(6). 666–673.e2. 32 indexed citations

Pérol, M., C. Chouaïd, David Pérol, et al.. (2012). Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(28). 3516–3524. 166 indexed citations

Girard, Nicolas, Camelia S. Sima, D. M. Jackman, et al.. (2011). Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma. European Respiratory Journal. 39(2). 366–372. 86 indexed citations

Reiman, Tony, Raymond Lai, E Paris, et al.. (2011). Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Annals of Oncology. 23(1). 86–93. 75 indexed citations

Rosell, Rafael, A. Vergnenègre, Baorui Liu, et al.. (2010). Biomarkers in lung oncology. Pulmonary Pharmacology & Therapeutics. 23(6). 508–514. 14 indexed citations

10.

Pirker, Robert, Felix Herth, Keith M. Kerr, et al.. (2010). Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology. 5(10). 1706–1713. 228 indexed citations

11.

Raz, Dan J., M. Ray, Biao He, et al.. (2008). A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma. Clinical Cancer Research. 14(17). 5565–5570. 60 indexed citations

12.

Skrzypski, Marcin, Ewa Jassem, Miquel Tarón, et al.. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research. 14(15). 4794–4799. 84 indexed citations

13.

Santarpía, Mariacarmela, Giuseppe Altavilla, Mireia Margelí Vila, et al.. (2008). PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Cancer Investigation. 26(10). 1044–1051. 11 indexed citations

14.

Queralt, Cristina, Clara Mayo, Miguel Ángel Molina‐Vila, et al.. (2007). High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). Cancer Research. 67. 5676–5676. 1 indexed citations

15.

Rosell, R., Nerea Martı́nez, Imane Chaib, et al.. (2007). Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients. Molecular Cancer Therapeutics. 6. 2 indexed citations

16.

Rosell, Rafael, Pedro Méndez, Dolores Isla, & Miquel Tarón. (2007). Platinum Resistance Related to a Functional NER Pathway. Journal of Thoracic Oncology. 2(12). 1063–1066. 29 indexed citations

17.

Rosell, Rafael, Mauricio Cuello, Fabiana Letizia Cecere, et al.. (2006). Usefulness of predictive tests for cancer treatment.. PubMed. 93(8). E101–8. 16 indexed citations

18.

Rosell, Rafael, Mauricio Cuello, Fabiana Letizia Cecere, et al.. (2006). Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Current Opinion in Oncology. 18(2). 135–143. 32 indexed citations

19.

Felip, Enriqueta, Miquel Tarón, Rafael Rosell, et al.. (2005). Clinical Significance of Hypoxia-Inducible Factor–1α Messenger RNA Expression in Locally Advanced Non–Small-Cell Lung Cancer After Platinum Agent and Gemcitabine Chemotherapy Followed by Surgery. Clinical Lung Cancer. 6(5). 299–303. 5 indexed citations

20.

Rosell, Rafael, Mariano Monzó, Vicente Alberola, et al.. (2002). Determinants of response and resistance to cytotoxics. Seminars in Oncology. 29(1). 110–118. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact